Details for New Drug Application (NDA): 212844
✉ Email this page to a colleague
NDA 212844 describes MEDROXYPROGESTERONE ACETATE, which is a drug marketed by Amneal, Amphastar Pharms Inc, Cipla, Eugia Pharma, Hikma, Hong Kong, Sandoz, Sun Pharm, Teva Pharms Usa, Xiromed, Barr, Duramed Pharms Barr, and Upsher Smith Labs, and is included in sixteen NDAs. It is available from twenty suppliers. Additional details are available on the MEDROXYPROGESTERONE ACETATE profile page.
The generic ingredient in MEDROXYPROGESTERONE ACETATE is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
The generic ingredient in MEDROXYPROGESTERONE ACETATE is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
Summary for 212844
| Tradename: | MEDROXYPROGESTERONE ACETATE |
| Applicant: | Eugia Pharma |
| Ingredient: | medroxyprogesterone acetate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 212844
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MEDROXYPROGESTERONE ACETATE | medroxyprogesterone acetate | INJECTABLE;INJECTION | 212844 | ANDA | Eugia US LLC | 55150-330 | 55150-330-01 | 1 SYRINGE in 1 CARTON (55150-330-01) / 1 mL in 1 SYRINGE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 150MG/ML | ||||
| Approval Date: | Aug 31, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
